<DOC>
	<DOCNO>NCT01263782</DOCNO>
	<brief_summary>The goal clinical research study learn know biomarker status help researcher find good treatment combination patient advance NSCLC . Researchers want use biomarker status decide drug ( bevacizumab , cixutumumab ) give combination carboplatin pemetrexed . The safety drug combination also study .</brief_summary>
	<brief_title>BATTLE-FL : Front-Line Biomarker-Integrated Treatment Study Non Small Cell Lung Cancer</brief_title>
	<detailed_description>The Study Drugs : Carboplatin design interfere growth cancer cell stop cell division , may cause cell die . Pemetrexed design block enzyme body play part tumor growth . Bevacizumab design block growth blood vessel supply nutrient necessary tumor growth . This may prevent slow growth cancer cell . Cixutumumab monoclonal antibody , mean attache specific target cancer cell . These target call IGF-1R help cancer cell grow divide . Cixutumumab design block receptor tumor cell may cause tumor grow . Study Groups Drug Administration ( Combination Therapy ) : If find eligible take part study , randomly assign ( roll dice ) 1 3 group . You equal chance assign group . Each cycle 21 day ( +/- 5 day ) . - If Group 1 , receive carboplatin pemetrexed Day 1 cycle . Carboplatin give vein 10 minute . Pemetrexed give vein 30 minute . - If Group 2 , receive bevacizumab , carboplatin , pemetrexed Day 1 cycle . Bevacizumab give vein 90 minute first dose , 60 minute second dose , 30 minute dos . Carboplatin give vein 10 minute . Pemetrexed give vein 30 minute . - If Group 3 , receive cixutumumab , carboplatin , pemetrexed Day 1 cycle . Cixutumumab give vein 60 minute . Carboplatin give vein 10 minute . Pemetrexed give vein 30 minute . Study Visits During Combination Therapy : If Group 3 , begin receive study drug , hear test . On Day 1 ( +/- 5 day ) Cycles 1 , 2 , 4 : - You physical exam , include measurement weight vital sign . - You ask drug may take side effect may . - Your performance status record . - Blood ( 3 teaspoon ) draw routine test . - If Group 2 , urine collect routine test . On Days 8 15 Cycle 1 : ° If Group 3 , blood ( 1 teaspoon ) drawn routine test . On Day 1 Cycle 3 : - You physical exam , include measurement weight vital sign . - You ask drug may take side effect may . - Your performance status record . - Blood ( 3 teaspoon ) draw routine test . - You CT scan and/or MRI scan chest ( abdomen doctor think need ) check status disease . - You MRI scan brain . - You chest x-ray check status disease . - If Group 2 , urine collect routine test . At time doctor think may need , blood ( 1 teaspoon ) drawn check well blood clot . Maintenance Therapy : After complete 4 cycle combination therapy , may eligible maintenance therapy . If Group 1 , receive pemetrexed vein 10 minute Day 1 ( ± 5 day ) every 21-day cycle . If Group 2 , receive pemetrexed vein 10 minute bevacizumab 30 minute Day 1 ( ± 5 day ) every 21-day cycle . If Group 3 , receive pemetrexed vein 10 minute cixutumumab vein 60 minute Day 1 ( ± 5 day ) every 21-day cycle . Study Visits During Maintenance Therapy : On Day 1 cycle : - You physical exam , include measurement weight vital sign . - You ask drug may take side effect may . - Your performance status record . - Blood ( 3 teaspoon ) draw routine test . - You CT scan and/or MRI scan chest ( abdomen doctor think need ) check status disease . - You MRI scan brain . - You chest x-ray check status disease . - If Group 2 , urine collect routine test . Length Study : You may continue take study drug ( ) long doctor think best interest . You longer able take study drug disease get bad intolerable side effect occur . Your participation study complete end-of-dosing visit follow-up . End-of-Dosing Visit : When go study reason , end-of-dosing visit . The following test procedure perform : - Your medical history record . - You complete physical exam , include measurement weight vital sign . - You ask drug may take side effect may . - Your performance status record . - Blood ( 3 teaspoon ) urine collect routine test . - You CT scan and/or MRI chest ( abdomen doctor think need ) check status disease . - You MRI scan brain . - You chest x-ray . - You ECG . - If Group 3 , hear test . Follow-Up : You follow-up every 4 week longer take study drug . You contact clinic visit phone . You call every 3 month 3 year ask cancer treatment may receive . This phone call take 10 minute . This investigational study . Carboplatin pemetrexed FDA approve commercially available treatment certain type NSCLC . Bevacizumab FDA approve commercially available treatment certain type colon rectal cancer , NSCLC , renal cell carcinoma . Cixutumumab FDA approve commercially available . At time , cixutumumab use research . Up 225 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Folic Acid Antagonists</mesh_term>
	<criteria>1 . The patient diagnosis pathologically confirm nonsquamous ( nonpredominant squamous ) NSCLC tumor biopsy and/or fineneedle aspiration . Mixed tumor categorize predominant cell type ; small cell element present , patient ineligible . 2 . The patient diagnosis either stage IIIB stage IV NSCLC recurrent NSCLC candidate curative treatment . Patients may chemotherapy frontline NSCLC treatment . 3 . The patient measurable NSCLC . 4 . The patient 's ECOG performance status &lt; /=2 study entry . 5 . The patient biopsy accessible tumor . 6 . The patient adequate hematologic function define absolute neutrophil count ( ANC ) &gt; /= 1,500/mm^3 , platelet count &gt; /= 100,000/mm^3 , WBC &gt; /= 3,000/ mm^3 , hemoglobin &gt; /= 9 g/dL . 7 . The patient adequate hepatic function define total bilirubin level &lt; /= 1.5 X upper limit normal ( Serum bilirubin &gt; /= 1.5x Upper Limit Normal set know Gilbert 's disease allow ) , alkaline phosphatase , AST ALT &lt; /= 2.5 X upper limit normal &lt; /= 5.0 x ULN liver metastases present . 8 . The patient adequate renal function define CrCl least 45ml/min . 9 . If patient brain metastasis , must stable ( treated and/or asymptomatic ) steroid least 2 week . 10 . The patient &gt; /= 18 year age . 11 . The patient sign informed consent . 12 . Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) duration study participation six ( 6 ) month discontinuation study drug . Childbearing potential defined woman menses within past 12 month , tubal ligation , hysterectomy bilateral oophorectomy . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . The patient , man , agree use effective contraception abstinence duration study participation six ( 6 ) month discontinuation study drug . 13 . The ability interrupt use NSAIDS two day ( 5 day longacting NSAIDs ) , day , 2 day follow administration Pemetrexed . 14 . The patient EGFR wild type . 1 . The patient receive prior definitive therapy ( chemotherapy , surgery , radiotherapy ) within 3 month initiate study drug within , 2 week localize palliative radiotherapy . Patients treat initial biologic therapy progress eligible ( drug within 4 week ) . Patients must recover acute toxic effect prior Day 1 Cycle 1 grade &lt; /= 1 baseline . 2 . Patients may prior biologic therapy antibody target VEGF , EGFR IGFR . 3 . The patient undergone prior thoracic abdominal surgery within 30 day study entry , exclude prior diagnostic biopsy . 4 . The patient history uncontrolled angina , arrhythmia , congestive heart failure . 5 . The patient inadequately control hypertension ( define systolic blood pressure &gt; 140 and/or diastolic &gt; 90 mm Hg antihypertensive medication ) . 6 . The patient history stroke transient ischemic attack within 6 month prior Day 1 Cycle 1 . 7 . The patient unable unwilling take folic acid , vitamin B12 supplementation , dexamethasone accord protocol . 8 . The patient neuropathy &gt; /= grade 2 . 9 . The patient history gastrointestinal fistula , perforation , abscess , inflammatory bowel disease , diverticulitis . 10 . The patient currently receive ongoing treatment fulldose warfarin equivalent ( , unfractionated and/or low molecular weight heparin ) . 11 . The patient pregnant ( confirm serum bHCG applicable ) breastfeeding . 12 . Presence significant third space fluid control drainage . 13 . Patients exclude Bevacizumab arm history hemoptysis ( &gt; /= ½ teaspoon bright red blood per episode ) within 3 month prior randomization . Patients exclude IMCA12 contain arm poorly control diabetes : HBA1C &gt; 8 % patient abnormally elevate fast serum glucose ( define &gt; 110 % ULN ) . Patients exclude know hypersensitivity drug . 14 . The patient 's tumor harbor EML4ALK fusion gene .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLL</keyword>
	<keyword>Nonsquamous cell</keyword>
	<keyword>Metastatic disease</keyword>
	<keyword>Cixutumumab</keyword>
	<keyword>IMC-A12</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>LY231514</keyword>
	<keyword>Alimta</keyword>
	<keyword>MTA</keyword>
	<keyword>Multitargeted Antifolate</keyword>
	<keyword>NSC-698037</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
</DOC>